Floatz Rating
B57/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02129075CT.gov A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mucosal Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant Flt3 Ligand (this asset) | National Cancer Institute (NCI) | P2 | B · 57 |
| Pembrolizumab | Melanoma Institute Australia | P3 | BB |
| Tyrosinase Peptide | University of Southern California | P3 | BB |
| Interferon Alfa-2B | Shanghai Junshi Bioscience Co., Ltd. | P3 | B |
| Ifa | Craig L Slingluff, Jr | P2 | B |
| Ipilimumab | Melanoma Institute Australia | P3 | B |
| Nivolumab | Fred Hutchinson Cancer Center | P2 | B |
| Carboplatin | Sun Yat-sen University | P3 | B |
| Cyclophosphamide | Melanoma Institute Australia | P3 | B |
+42 more in the Mucosal Melanoma cohort
Other indications for Recombinant Flt3 Ligand
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P2 | B · 61 |
| Leukemia | — | P3 | B · 59 |
| Ocular Melanoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Recombinant Flt3 Ligand in Mucosal Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-flt3-ligand-mucosal-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →